NCT03144882

Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Completed NA Last updated 9 May 2017

What this trial tests

NA trial testing Curcumin Pill in Hemodialysis Complication in 71 participants. Completed in 2 February 2017.

Timeline

2 February 2015

Primary endpoint
2 February 2016

2 February 2017

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	71
Start date	2 February 2015
Primary completion	2 February 2016
Estimated completion	2 February 2017

Drugs / interventions tested

• Curcumin Pill — full drug profile →
• Placebo

Conditions studied

• Hemodialysis Complication — all drugs for Hemodialysis Complication →
• Hemodialysis-Induced Symptom — all drugs for Hemodialysis-Induced Symptom →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

18 and older, any sex, with Hemodialysis Complication or Hemodialysis-Induced Symptom. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Programmed ingestion of turmeric has no adverse effects and reduces plasma level of hs-CRP, IL-6 and TNF-α accompanying with increases albumin levels in hemodialysis patients. Turmeric can be considered as an effective anti-inflammatory supplement in hemodialysis patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Reconnoitering the Therapeutic Role of Curcumin in Disease Prevention and Treatment: Lessons Learnt and Future Directions.
   Sivani BM, Azzeh M, Patnaik R, Pantea Stoian A, et al · · 2022 · cited 26× · PMID 35888763 · DOI 10.3390/metabo12070639